How I Rate AstraZeneca Plc As A ‘Buy And Forget’ Share

Is AstraZeneca plc (LON: AZN) a good share to buy and forget for the long term?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m analysing some of the most popular companies in the FTSE 100 to establish if they are attractive long-term buy and forget investments.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

What is the sustainable competitive advantage?

At the end of 2012, AstraZeneca was one of the largest pharmaceutical companies in the world, employing over 50,000 people worldwide. Furthermore, AstraZeneca’s Crestor treatment is the world’s eighth bestselling drug, with sales of around $6.3bn.

Indeed, due to its size, AstraZeneca has a certain dominance over the biotechnology market, as many smaller competitors cannot compete with the firm’s financial power and research capabilities.  

Additionally, as AstraZeneca has exclusive production rights for its own treatments, the company can set prices, giving itself a wide profit margin. In particular, even after the loss of some exclusive manufacturing rights last year (which caused a 15% drop in revenue), AstraZeneca’s net profit margin still came in at 22%.

Having said that, AstraZeneca is facing fierce competition from generic producers, which are now manufacturing cheaper versions of some key drugs, after the company’s exclusive manufacturing rights expired last year.

Nonetheless, AstraZeneca’s size and global exposure mean that the company is able to stay ahead of the game, as the firm’s brand attracts talented personal.

Moreover, many larger pharmaceutical companies are now forming research partnerships, in an attempt to offset the stream of patent expirations that are affecting the industry.

Company’s long-term outlook?

With the spectre of disease always present, the demand for AstraZeneca’s products will remain constant, or even grow over the long term, as long as the company can produce treatments that are effective.

It appears that AstraZeneca is well placed to do this. Indeed, the firm has 84 new treatments under development, 13 of which are in the final stages of testing.

Furthermore, AstraZeneca has a strong balance sheet with net debt of only $2bn — a debt to asset ratio of 4%, giving the company plenty of room to acquire smaller competitors as well as new treatments for its pipeline.

Foolish summary

Overall, there will always be a strong demand for AstraZeneca’s products and the company has plenty of treatments under development that will allow it to stay ahead of the game. Additionally, with an almost debt free balance sheet, the company has plenty of room to spend for future growth.

So overall, I rate AstraZeneca as a very good share to buy and forget.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict

> Rupert does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

4 penny stocks I’d love to buy for my Xmas stocking!

I'm hoping to buy these top penny stocks when I next have the opportunity. I think they could be some…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Why I believe the lagging FTSE 250 is a rare opportunity to buy cheap shares now

The FTSE 250 is showing some attractive numbers and they suggest some cracking value among businesses listed in the index.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is this FTSE 250 TV giant one of the best opportunities on the market right now?

A staple name among UK television lovers, this FTSE 250 stock has fallen substantially. Is it time to buy the…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Could this 2.5% yielding penny stock soar in 2024 and beyond?

This penny stock has struggled throughout 2023 but could the new year provide it with a much needed positive momentum…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to buy in December [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Close-up of British bank notes
Investing Articles

With £500 I’d start a passive income portfolio with these UK shares

Owning shares in an established business can be a great source of passive income. And Stephen Wright thinks now is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I’d buy these FTSE 100 and small cap stocks in 2024 to target a second income!

This FTSE share offers a 6% dividend yield and trades on a rock-bottom P/E ratio. Here's why I'll buy it,…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Here’s one excellent FTSE 100 value stock investors should consider buying

Sumayya Mansoor explains why this packaging giant is currently in value stock territory and should be on investors radars.

Read more »